These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 1587939)

  • 1. The synergistic effects of clomiphene citrate and human menopausal gonadotrophin in the folliculogenesis of stimulated cycles as assessed by the gonadotrophin-releasing hormone antagonist Nal-Glu.
    Cassidenti DL; Paulson RJ; Lobo RA; Sauer MV
    Hum Reprod; 1992 Mar; 7(3):344-8. PubMed ID: 1587939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation.
    Frydman R; Cornel C; de Ziegler D; Taieb J; Spitz IM; Bouchard P
    Fertil Steril; 1991 Nov; 56(5):923-7. PubMed ID: 1936328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneous luteinizing hormone surges can be reliably prevented by the timely administration of a gonadotrophin releasing hormone antagonist (Nal-Glu) during the late follicular phase.
    Frydman R; Cornel C; de Ziegler D; Taieb J; Spitz IM; Bouchard P
    Hum Reprod; 1992 Aug; 7(7):930-3. PubMed ID: 1430131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of a gonadotropin releasing hormone (GnRH) antagonist and exogenous gonadotropins to unstimulated in vitro fertilization (IVF) cycles: physiologic observations and preliminary experience.
    Paulson RJ; Sauer MV; Lobo RA
    J Assist Reprod Genet; 1994 Jan; 11(1):28-32. PubMed ID: 7949832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intermittent and continuous use of a gonadotropin-releasing hormone antagonist (Nal-Glu) in in vitro fertilization cycles: a preliminary report.
    Cassidenti DL; Sauer MV; Paulson RJ; Ditkoff EC; Rivier J; Yen SS; Lobo RA
    Am J Obstet Gynecol; 1991 Dec; 165(6 Pt 1):1806-10. PubMed ID: 1750479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of gonadotrophin-releasing hormone agonists administered as desensitizing or flare protocols on hormonal function in the luteal phase of hyperstimulated cycles.
    Norman RJ; Warnes GM; Wang X; Kirby CA; Matthews CD
    Hum Reprod; 1991 Feb; 6(2):206-13. PubMed ID: 1905309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
    Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R
    Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH.
    Dubourdieu S; Charbonnel B; D'Acremont MF; Carreau S; Spitz IM; Bouchard P
    J Clin Endocrinol Metab; 1994 Feb; 78(2):343-7. PubMed ID: 8106622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follicle-stimulating hormone as a prognostic indicator in clomiphene citrate/human menopausal gonadotrophin-stimulated cycles for in-vitro fertilization.
    Tanbo T; Dale PO; Abyholm T; Stokke KT
    Hum Reprod; 1989 Aug; 4(6):647-50. PubMed ID: 2506220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovulation triggering in clomiphene citrate-stimulated cycles: human chorionic gonadotropin versus a gonadotropin releasing hormone agonist.
    Schmidt-Sarosi C; Kaplan DR; Sarosi P; Essig MN; Licciardi FL; Keltz M; Levitz M
    J Assist Reprod Genet; 1995 Mar; 12(3):167-74. PubMed ID: 8520180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
    Ragni G; Vegetti W; Baroni E; Colombo M; Arnoldi M; Lombroso G; Crosignani PG
    Hum Reprod; 2001 Nov; 16(11):2258-62. PubMed ID: 11679500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human prolactin release induced by follicle stimulating hormone, luteinizing hormone and human chorionic gonadotrophin.
    Crosignani PG; Maini MC; Negri E; Ragni G
    Hum Reprod; 1991 Sep; 6(8):1070-3. PubMed ID: 1806563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovulation induction in clomiphene-resistant anovulatory women: differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone.
    Hoffman DI; Lobo RA; Campeau JD; Tsai HM; Holmberg EA; Ono T; Frederick JJ; Platt LD; diZerega GS
    J Clin Endocrinol Metab; 1985 May; 60(5):922-7. PubMed ID: 3920235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women.
    Ditkoff EC; Cassidenti DL; Paulson RJ; Sauer MV; Paul WL; Rivier J; Yen SS; Lobo RA
    Am J Obstet Gynecol; 1991 Dec; 165(6 Pt 1):1811-7. PubMed ID: 1750480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clomiphene citrate and hMG: an alternative stimulation protocol for selected failed in vitro fertilization patients.
    Benadiva CA; Davis O; Kligman I; Liu HC; Rosenwaks Z
    J Assist Reprod Genet; 1995 Jan; 12(1):8-12. PubMed ID: 7580013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists.
    Hall JE; Whitcomb RW; Rivier JE; Vale WW; Crowley WF
    J Clin Endocrinol Metab; 1990 Feb; 70(2):328-35. PubMed ID: 2105329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation.
    Christin-Maitre S; Olivennes F; Dubourdieu S; Chabbert-Buffet N; Charbonnel B; Frydman R; Bouchard P
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):721-6. PubMed ID: 10848876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.